Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 6/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76832 | 0.98 | KDM4C (0.41) | KDM4CMEN1GAAKMT2ACTSK | |
| SCHEMBL21834933 | 0.95 | KDM4C (0.39) | KDM4CMEN1GAAKMT2ACTSK | |
| SCHEMBL2542864 | 0.90 | KDM4C (0.36) | KDM4CMEN1GAAKMT2ACTSK | |
| SCHEMBL2537978 | 0.90 | KDM4C (0.36) | KDM4CMEN1GAAKMT2ACTSK | |
| SCHEMBL20295137 | 0.82 | GAA (0.39) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL14276786 | 0.81 | TDP1 (0.39) | MEN1GAAKMT2ACTSKTDP1 | |
| SCHEMBL12845831 | 0.80 | MEN1 (0.38) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL25229366 | 0.79 | MEN1 (0.44) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL2512445 | 0.79 | MEN1 (0.40) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL753141 | 0.78 | KDM4C (0.43) | KDM4CGAADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008062-B1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-04-05 | — | — | EP | disclosed |
| US-9586958-B2 | Prodrug derivatives of substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20160207915-A1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| EP-3008062-A2 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| CN-105377848-A | Prodrug derivatives of substituted triazolopyridines | Bayer Pharma AG | 2016-03-02 | — | — | CN | disclosed |
| WO-2014198647-A2 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207915-A1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | TK1, PNKP, MPST | KDM4C 3800/4885MEN1 1388/4885GAA 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.